Fig. 6: Evaluation of in vivo treatment efficacy of PLX-NP-P-aPD-1@Gel in different tumor recurrence models including the sarcoma S180 tumor model and B16F10 melanoma model in T cell-deficient mice.
a Tumor growth curves among different treatment groups in sarcoma S180 tumor recurrence model (n = 6 mice). Saline; NP-P@Gel, blank nanoparticles and unmodified platelets co-loaded hydrogel; PLX-aPD-1@Gel, free PLX and aPD-1 co-loaded hydrogel; PLX-NP@Gel, PLX-NP loaded hydrogel; P-aPD-1@Gel, P-aPD-1 loaded hydrogel; PLX-NP+P-aPD-1, free PLX-NP and P-aPD-1; PLX-NP-P-aPD-1@Gel, PLX-NP and P-aPD-1 co-loaded hydrogel. The doses of PLX and aPD-1 were 5 mg/kg and 0.1 mg/kg, respectively. b The images of representative tumors after different treatments on day 21 (n = 6 mice). c Survival curves of the mice in different treatment groups in the S180 tumor recurrence model (n = 6 mice). Data were analyzed with Log-rank (Mantel-Cox) test, PLX-NP-P-aPD-1@Gel vs. PLX-NP+P-aPD-1: **P = 0.0031. d Representative bioluminescence images of B16F10 tumor-bearing Rag−/− mice following different treatments on day 0, day 7, day 14, day 21 (n = 5 mice). e Survival curves of the mice treated with different treatment groups in B16F10 tumor recurrence model in Rag−/− mice (n = 5 mice). f Schematic illustration of the establishment and treatment strategy of a double tumor model. g Tumor growth curve of the distant tumor after different treatments (PLX-NP-P-aPD-1@Gel vs. PLX-NP+P-aPD-1: ***P < 0.0001). Data are presented as mean ± s.d. (n = 6 mice) and analyzed with two-way ANOVA followed by Tukey’s multiple comparison test. Source data are provided as a Source Data file.
